• linkedin
  • Increase Font
  • Sharebar

    CE: Pharmacist Perspective on the CDC Guideline for Prescribing Opioids for Chronic Pain


    March 2017

    Session code for pharmacists: 17DT03-FXK22
    Session code for pharmacy technicians: 17DT03-TPV68
    This month’s CE activity, “Pharmacist perspective on the CDC guideline for prescribing opioids for chronic pain” is open for pharmacists and pharmacy technicians.

    Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics.

    The goal of this activity is to educate pharmacists and pharmacy technicians about identifying the risks and benefits of opioid therapy and improving its long-term safety. 

    To read and print the article with TEST QUESTIONS, click here.

    To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code for pharmacists: 17DT03-FXK22 or the session code for pharmacy technicians: 17DT03-TPV68 

    Copy the appropriate session code above before logging into the Online CE Center. When the page for the Online CE Center opens, paste the session code into the appropriate field, under your NABP ID.

    First-time users must pre-register in the Online CE Center.


    The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php.

    To review your registration page to ensure your data is up to date, or to register,
    go to https://web2.uconn.edu/pharmacyce/program_register.php.

    For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/.

    Lisa M. Holle, PharmD, BCOP, FHOPA
    Associate Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available